| Not Yet Recruiting | Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica NCT07286214 | Sanofi | Phase 4 |
| Not Yet Recruiting | Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rhe NCT07394478 | Hôpital NOVO | — |
| Not Yet Recruiting | Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalg NCT07132164 | University Hospital, Brest | — |
| Recruiting | A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immun NCT06647134 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) NCT06331312 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GC NCT06130540 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica NCT06172361 | Zhejiang University | Phase 3 |
| Recruiting | DANIsh VASculitis Database (DANIVAS) NCT05935709 | Aarhus University Hospital | — |
| Recruiting | Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic NCT06460142 | University of Bonn | — |
| Recruiting | Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica. NCT06011512 | Salome Kristensen | — |
| Completed | Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper NCT05767034 | Novartis Pharmaceuticals | Phase 3 |
| Active Not Recruiting | Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR NCT05533164 | Sint Maartenskliniek | Phase 3 |
| Completed | Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed NCT05533125 | Sint Maartenskliniek | Phase 3 |
| Active Not Recruiting | Treat-to-target Prednisolon Taper in Patients With Polymyalgia Rheumatica NCT05636501 | Aarhus University Hospital | N/A |
| Completed | A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR) NCT05436652 | Sparrow Pharmaceuticals | Phase 2 |
| Completed | Validation of the PMR Activity Score and Evolution of Patient-reported Outcomes in Patients With Polymyalgia R NCT05542316 | Universitaire Ziekenhuizen KU Leuven | — |
| Recruiting | Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency NCT05435781 | Marianne Christina Klose | Phase 4 |
| Terminated | A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR) NCT06281236 | Sparrow Pharmaceuticals | Phase 1 |
| Terminated | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheu NCT04972968 | AbbVie | Phase 2 |
| Completed | Immunopathology of Polymyalgia Rheumatica on Shoulder Bursae's Biopsies NCT04727879 | University Hospital, Brest | N/A |
| Recruiting | PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS NCT04664465 | University Hospital, Brest | — |
| Unknown | Polymyalgia Rheumatica Associated to Primary Sjogren Syndrome NCT05312944 | University Hospital, Brest | — |
| Completed | Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica NCT04799262 | RenJi Hospital | Phase 2 |
| Completed | The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata NCT04239521 | Momentum Data | — |
| Active Not Recruiting | Improved Diagnostics and Monitoring of Polymyalgia Rheumatica NCT04519580 | Kresten Krarup Keller | — |
| Recruiting | Rheumatology Patient Registry and Biorepository NCT04402086 | Yale University | — |
| Unknown | Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica NCT04062006 | Peking University People's Hospital | Phase 2 |
| Terminated | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease NCT03656627 | Alliance Foundation Trials, LLC. | Phase 1 |
| Unknown | Treatment With Leflunomide in Patients With Polymyalgia Rheumatica NCT03576794 | Elisabeth Brouwer | Phase 3 |
| Unknown | Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS NCT03632187 | University Hospital, Brest | Phase 3 |
| Terminated | Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica NCT03600818 | Sanofi | Phase 3 |
| Withdrawn | Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica NCT02899026 | GlaxoSmithKline | Phase 3 |
| Completed | A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in NCT03263715 | Medical University of Vienna | Phase 3 |
| Unknown | Polymyalgia Rheumatica and Giant Cell Arteritis NCT02985424 | Svendborg Hospital | — |
| Completed | Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEM NCT02908217 | University Hospital, Brest | Phase 3 |
| Terminated | Delayed Release Prednisone in PMR NCT02702778 | Dinora, Inc. | Phase 2 |
| Unknown | PatientSpot Formerly Known as ArthritisPower NCT03840928 | Global Healthy Living Foundation | — |
| Completed | Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica NCT02888496 | University Hospital, Brest | — |
| Terminated | A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR NCT01821040 | Mundipharma Research Limited | Phase 3 |
| Completed | Tocilizumab Effect iN pOlymyalgia Rheumatica NCT01713842 | University Hospital, Brest | Phase 2 |
| Completed | Melanocortin Gene Expression in Lymphocytes of Polymyalgia Patients NCT05681676 | Aalborg University | — |
| Terminated | A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica NCT01364389 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica NCT00982332 | Bnai Zion Medical Center | N/A |
| Completed | Timed Release Tablet Prednisone in Polymyalgia Rheumatica NCT00836810 | University Hospitals Bristol and Weston NHS Foundation Trust | Phase 2 / Phase 3 |
| Completed | Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica NCT00847236 | Lahey Clinic | — |
| Completed | Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients NCT01169597 | University of Genova | Phase 4 |
| Completed | Etanercept Treatment in the Early Course of Polymyalgia Rheumatica NCT00524381 | Bispebjerg Hospital | Phase 3 |
| Unknown | Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica NCT01423591 | Hospital Universitario Marqués de Valdecilla | Phase 3 |
| Recruiting | Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) NCT04102930 | University of Leeds | — |
| Completed | Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. NCT00138983 | UMC Utrecht | Phase 3 |
| Completed | Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity NCT03941184 | Mayo Clinic | — |